Insulet Stock

Insulet Liabilities

The The Liabilities of Insulet (PODD) as of Sep 15, 2026 is 1.68 B USD. In the previous year, The Liabilities was 1.88 B USD — a change of -10.71% (lower).

Liabilities

1.68 BUSD

YoY

-10.71%

Last updated:

In 2026, Insulet's total liabilities amounted to 1.68 B USD, a -10.71% difference from the 1.88 B USD total liabilities in the previous year.

The Insulet Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
716.65 M USD
Jan 1, 2019
1.07 B USD
Jan 1, 2020
1.27 B USD
Jan 1, 2021
1.49 B USD
Jan 1, 2022
1.77 B USD
Jan 1, 2023
1.86 B USD
Jan 1, 2024
1.88 B USD
Jan 1, 2025
1.68 B USD
The Insulet Liabilities history
YEARLiabilitiesYoY
1.68 BUSD-10.71%
1.88 BUSD+1.11%
1.86 BUSD+4.55%
1.77 BUSD+18.91%
1.49 BUSD+17.58%
1.27 BUSD+18.96%
1.07 BUSD+48.89%
716.65 MUSD+8.87%
658.23 MUSD+67.28%
393.50 MUSD+63.23%
241.08 MUSD+10.42%
218.33 MUSD
Access this data via the Eulerpool API

Insulet Stock analysis

What does Insulet do? Insulet Corp is an American company that was founded in 2000 and is headquartered in Acton, Massachusetts. Its goal is to improve the quality of life for people with diabetes by developing innovative products that make living with this chronic disease easier. Insulet Corp is known for its product "OmniPod." The OmniPod is a wireless, portable disposable insulin pump system that offers an alternative option to traditional pumping and insulin delivery systems. The OmniPod system consists of two small devices: a pod worn on the skin and a PDM (Personal Diabetes Manager) that regulates insulin delivery. The pod contains an insulin reservoir that communicates wirelessly with the PDM. The insulin dose is administered directly into the body without needles or tubes. Insulet Corp is also introducing the "OmniPod DASH System." This new system combines the proven design of the OmniPod pod with a new color touchscreen handheld device that allows for even easier operation. The DASH system also offers the ability to control insulin dosing from a smartphone, which can be taken with diabetics wherever they go. The success of the OmniPod system has made Insulet Corp a leading company in the diabetes industry. The company has also developed and introduced products and services in other areas of diabetes treatment. Insulet Corp has developed another product called "Amigo." This product is a personalized travel and training program for people who require insulin. Amigo offers specialized and personalized training to support diabetics in managing complex situations. It also offers diet and exercise plans to make living with diabetes easier. Insulet Corp has also developed a software called "OmniPod Horizon." This software is a closed-loop system that automatically adjusts insulin dosing to keep blood sugar levels within the target range. The system is currently in the development phase and is expected to be released in 2020. Insulet Corp has also developed a program called the "OmniPod Partner Program," which targets doctors and pharmacists. The program provides training and educational materials for healthcare providers to help them better treat and manage their patients. Since 2009, Insulet Corp has been listed on the NASDAQ stock exchange and has continuously evolved since then. The company currently has over 1500 employees and operates in North America, Europe, and the Middle East. Insulet Corp is a company focused on the development of innovative, life-changing products and services. It is expected to continue to play a significant role in improving the quality of life for people with diabetes in the future. Insulet is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Insulet's Liabilities

Insulet's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Insulet's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Insulet's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Insulet's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Insulet’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Insulet stock

The Liabilities of Insulet is 1.68 B USD in 2026.

The Liabilities of Insulet changed from 1.88 B USD to 1.68 B USD, representing a -10.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Insulet since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Insulet historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Insulet

All Key Metrics — Insulet